MDPLF
Medicus Pharma Ltd., a biotech/life sciences company, focuses on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. It is developing SkinJect with an indication for basal cell carcinoma. The company is headquartered in Toronto, Canada.
MDPLF (MDPLF) - Net Assets
Latest net assets as of June 2024: $6.45 Million USD
Based on the latest financial reports, MDPLF (MDPLF) has net assets worth $6.45 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.78 Million) and total liabilities ($2.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.45 Million |
| % of Total Assets | 73.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MDPLF - Net Assets Trend (2021–2023)
This chart illustrates how MDPLF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MDPLF (2021–2023)
The table below shows the annual net assets of MDPLF from 2021 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $805.80K | +106.61% |
| 2022-12-31 | $-12.20 Million | -16.11% |
| 2021-12-31 | $-10.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MDPLF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 847652200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $19.98 Million | 2479.83% |
| Total Equity | $805.80K | 100.00% |
MDPLF Competitors by Market Cap
The table below lists competitors of MDPLF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DONGFANG ELEC -H-
BE:DEU
|
$25.92K |
|
COFFEE HOLDING (E6U.SG)
STU:E6U
|
$25.94K |
|
ZAPTEC ASA NK -015
F:6I4
|
$25.95K |
|
A3 Mercados S.A.
BA:A3
|
$25.96K |
|
ADVANCED EMISSIONS
BE:OXQ1
|
$25.91K |
|
IREN (TZ8.SG)
STU:TZ8
|
$25.90K |
|
Wins Finance Holdings Inc
PINK:WINSF
|
$25.89K |
|
SYNECTICS
BE:RNR
|
$25.89K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MDPLF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -12,198,032 to 805,800, a change of 13,003,832.
- Net loss of 6,784,140 reduced equity.
- Other factors increased equity by 19,787,972.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.78 Million | -841.91% |
| Other Changes | $19.79 Million | +2455.69% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares MDPLF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 54.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.65 | $2.70 | x |
| 2022-12-31 | $-0.76 | $2.70 | x |
| 2023-12-31 | $0.05 | $2.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MDPLF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -841.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.35x
- Recent ROE (-841.91%) is below the historical average (-280.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.00 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-472.58K |
| 2023 | -841.91% | 0.00% | 0.00x | 2.35x | $-6.86 Million |
Industry Comparison
This section compares MDPLF's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MDPLF (MDPLF) | $6.45 Million | 0.00% | 0.36x | $25.91K |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |